AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28285751
Drug: Oxandrolone (0.06
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxandrolone (0.06 mg/kg daily)
Trial: 21748366
Drug: Testosterone (T)
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone (T) only at 5 or 10 g/day
Trial: 21748366
Drug: Testosterone (T)
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone (T) + recombinant human growth hormone (rhGH) at 0, 3.0 or 5.0 μg/kg/day
Trial: 18978489
Drug: Galantamine (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galantamine (24 mg/d)
Trial: 9613540
Drug: 50 mL
RxNorm normalized name: TPN Bag 250 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mL 0.125% bupivacaine (n = 18)
Trial: 9613540
Drug: 50 mL
RxNorm normalized name: TPN Bag 250 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mL 0.25% bupivacaine (n = 20)
Trial: 9613540
Drug: 50 mL
RxNorm normalized name: TPN Bag 250 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mL saline (Control; n = 21)
Trial: 7627864
Drug: Non-drainage during
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-drainage during saline infusion
Trial: 7627864
Drug: Non-drainage during
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-drainage during mannitol infusion
Trial: 6111295
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no clemastine treatment)
Trial: 24220376
Drug: Merocel nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Merocel nasal tampon within glove finger moistened with tetracaine 0.25% solution, removed after 48 hours
Trial: 28483774
Drug: Intravenous tissue
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tissue plasminogen activator (IV tPA) alone
Trial: 25777831
Drug: Intravenous tissue
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tissue plasminogen activator (IV tPA) + Solitaire revascularization device
Trial: 23740224
Drug: Combined endpoint
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined endpoint (Dabigatran + Warfarin)
Trial: 9187886
Drug: Aflurax 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aflurax 1200 mg, two tablets four times daily
Trial: 24651151
Drug: BoNT‐A injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BoNT‐A injection of the Rectus Femoris (RF) muscle
Trial: 17998023
Drug: Caffeine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (200 mg taken twice a day for 7 days)
Trial: 15824911
Drug: Ciclesonide via
RxNorm normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciclesonide via hydrofluoroalkane metered-dose inhaler
Trial: 15824911
Drug: Budesonide via
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide via chlorofluorocarbon metered-dose inhaler
Trial: 2501104
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of nifedipine and sodium cromoglycate
Trial: 26516142
Drug: Adjuvanted and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvanted and unadjuvanted vaccine groups
Trial: 24810369
Drug: elosulfase alfa
RxNorm normalized name: Elosulfase alfa
DrugBank: Elosulfase alfa (DB09051)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: elosulfase alfa 2.0 mg/kg/week
Trial: 24810369
Drug: elosulfase alfa
RxNorm normalized name: Elosulfase alfa
DrugBank: Elosulfase alfa (DB09051)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: elosulfase alfa 2.0 mg/kg/every other week (qow)
Trial: 23573238
Drug: Reduced glycerin
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced glycerin formulation of tenofovir 1% gel
Trial: 30148449
Drug: Heparin 5,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin 5,000 µ/mL
Trial: 14517193
Drug: Moxidectin (MOX)
DrugBank: Moxidectin (DB11431)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moxidectin (MOX) 3 mg
Trial: 14517193
Drug: Moxidectin (MOX)
DrugBank: Moxidectin (DB11431)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moxidectin (MOX) 9 mg
Trial: 14517193
Drug: Moxidectin (MOX)
DrugBank: Moxidectin (DB11431)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moxidectin (MOX) 18 mg
Trial: 14517193
Drug: Moxidectin (MOX)
DrugBank: Moxidectin (DB11431)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moxidectin (MOX) 36 mg
Trial: 14517193
Drug: Moxidectin (MOX)
DrugBank: Moxidectin (DB11431)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moxidectin (MOX) with high-fat breakfast (9 mg)
Trial: 14517193
Drug: Moxidectin (MOX)
DrugBank: Moxidectin (DB11431)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moxidectin (MOX) with high-fat breakfast (36 mg)
Trial: 10863679
Drug: Cognitive-behavioral skills
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral skills training (CBST) treatment
Trial: 10863679
Drug: Combined (biofeedback/CBST)
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined (biofeedback/CBST) treatment
Trial: 290726
Drug: Aspirin (650
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (650 mg)
Trial: 3515927
Drug: Codeine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Codeine (60 or 120 mg)
Trial: 23551622
Drug: Tadalafil 5
RxNorm normalized name: tadalafil 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil 5 mg once a day (OaD)
Trial: 22429760
Drug: Sildenafil 100
RxNorm normalized name: sildenafil 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 100 mg as needed (PRN)
Trial: 16793612
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (routine blood transfusion and fluid infusion)
Trial: 10669060
Drug: Progressive increase
RxNorm normalized name: Incruse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progressive increase in magnitude of reinforcement for abstinence with a reset contingency for drug use
Trial: 22246026
Drug: Sumatriptan (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan (6 mg subcutaneous)
Trial: 1587064
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg racemic mephenytoin alone
Trial: 21641663
Drug: Anticonvulsants and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticonvulsants and benzodiazepines
Trial: 9640079
Drug: IHD with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IHD with HLP without aspirin
Trial: 2868207
Drug: Intravenous hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous hydrocortisone in addition to high-dose oral prednisolone and standard bronchodilator therapy
Trial: 2868207
Drug: High-dose oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose oral prednisolone and standard bronchodilator therapy
Trial: 24582042
Drug: Iodixanol-320 at
RxNorm normalized name: Iodixanol
DrugBank: Iodixanol (DB01249)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iodixanol-320 at 5.0 mL/sec flow rate (group 3)
Trial: 24582042
Drug: Iodixanol-320 at
RxNorm normalized name: Iodixanol
DrugBank: Iodixanol (DB01249)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iodixanol-320 at 6.2 mL/sec flow rate (group 2)
Trial: 24582042
Drug: Iomeprol-400 at
RxNorm normalized name: IOMEPROL
DrugBank: Iomeprol (DB11705)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iomeprol-400 at 5.0 mL/sec flow rate (group 1)
Trial: 22483976
Drug: Intralipid 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralipid 40 mL/h
Trial: 31679431
Drug: Liuweibuqi (LWBQ)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liuweibuqi (LWBQ) capsules (low dose: 1 LWBQ capsule + 8 starch capsules; medium dose: 3 LWBQ capsules + 6 starch capsules; high dose: 9 LWBQ capsules) for 30 days, 3 times a day
Trial: 31679431
Drug: Starch capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starch capsules (control group)
Trial: 15200747
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (CT)
Trial: 9243353
Drug: Selegiline (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selegiline (10 mg)
Trial: 19129751
Drug: EVT 301
RxNorm normalized name: EVT 201
DrugBank: EVT 201 (DB05721)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EVT 301 (75 mg) in AD subjects
Trial: 17389559
Drug: Transdermal contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal contraceptive patch
Trial: 17957909
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive (ethinyl estradiol 30 microg and levonorgestrel 150 microg)
Trial: 7539854
Drug: Doxazosin (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin (all doses)
Trial: 2278720
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose metoclopramide (M)
Trial: 23837939
Drug: Intravenous cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cyclophosphamide pulse therapy (CPT)
Trial: 30298667
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral prednisolone
Trial: 21383283
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus bevacizumab (BV)
Trial: 12939564
Drug: lercanidipine 10
RxNorm normalized name: lercanidipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lercanidipine 10 mg
Trial: 15543081
Drug: lercanidipine 20
RxNorm normalized name: lercanidipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lercanidipine 20 mg
Trial: 10517716
Drug: Raloxifene (combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene (combined 60 mg/d and 120 mg/d)
Trial: 8529160
Drug: 1% idoxuridine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% idoxuridine ointment
Trial: 8529160
Drug: 2% trifluorothymidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% trifluorothymidine ointment
Trial: 28705190
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose aspirin (80 mg once daily)
Trial: 9532989
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose aspirin
Trial: 23432755
Drug: high-level tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: high-level tacrolimus (TAC, 8-12 μg/L) and low-level sirolimus (SIR, 3-7 μg/L) (TACH/SIRL, n=149)
Trial: 21029339
Drug: Aliskiren 150
RxNorm normalized name: aliskiren 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren 150 mg
Trial: 11789591
Drug: SKI 306X
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SKI 306X 200 mg t.i.d.
Trial: 11789591
Drug: SKI 306X
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SKI 306X 400 mg t.i.d.
Trial: 11789591
Drug: SKI 306X
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SKI 306X 600 mg t.i.d.
Trial: 9677830
Drug: Anticardiolipin antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticardiolipin antibodies (IgG and IgM) measured at 6 months
Trial: 30064403
Drug: Cognitive Orientation
RxNorm normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Orientation to daily Occupational Performance (CO‐OP) only
Trial: 30064403
Drug: Cognitive Orientation
RxNorm normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Orientation to daily Occupational Performance (CO‐OP) + splint
Trial: 27296249
Drug: No special
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No special treatment preparation (control group, n=394).
Trial: 23687231
Drug: Dextrose 5%
RxNorm normalized name: Dextrose 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose 5% in lactated Ringer's solution (group D)
Trial: 18492837
Drug: CHO+PRO treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO+PRO treatment
Trial: 16793810
Drug: Metoprolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (100 mg controlled and extended release)
Trial: 3009077
Drug: Beet-fibre meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beet-fibre meal (10.8 g dietary fibre from sugar beet)
Trial: 20139427
Drug: Oral levonorgestrel
RxNorm normalized name: levonorgestrel Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral levonorgestrel (0.75 mg x 4, at 24 h intervals on LH + 1 to LH + 4; n = 8)
Trial: 18248661
Drug: Intraduodenal PHA
RxNorm normalized name: PHA-767491
DrugBank: PHA-767491 (DB17043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraduodenal PHA (150 microg, 1.5 mg, 15 mg)
Trial: 18248661
Drug: CCK(1) receptor
RxNorm normalized name: CCK-8
DrugBank: Sincalide (DB09142)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CCK(1) receptor antagonist dexloxiglumide
Trial: 15215806
Drug: Warfarin (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (target INR 2.5)
Trial: 14978854
Drug: Ximelagatran (36
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ximelagatran (36 mg twice daily)
Trial: 7844607
Drug: Primary chemotherapy
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary chemotherapy with cisplatin 60 mg/m2 and epirubicin 110 mg/m2 administered at 3-week intervals for three cycles, followed by pelvic radiotherapy.
Trial: 7844607
Drug: Combined modality
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined modality treatment (chemotherapy followed by radiotherapy).
Trial: 2333832
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg oral caffeine
Trial: 9846599
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg oral caffeine
Trial: 2333832
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg oral caffeine
Trial: 313353
Drug: Intravenous vasopressin
RxNorm normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous vasopressin (IVV) started at 0.3 U/min, increased to 1.5 U/min as needed
Trial: 23032746
Drug: Vismodegib (GDC‐0449;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vismodegib (GDC‐0449; 150 mg daily)
Trial: 17166775
Drug: Lamotrigine (LTG)
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lamotrigine (LTG) adjunctive treatment
Trial: 10930900
Drug: Omeprazole MUPS
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole MUPS 20 mg
Trial: 8934728
Drug: FEC with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FEC with high-dose infusional 5-fluorouracil (750 mg/m2 per day/days 1 to 5)
Trial: 233444
Drug: tiapride 300
RxNorm normalized name: tiapride
DrugBank: Tiapride (DB13025)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tiapride 300 mg/day
Trial: 30157242
Drug: subtype C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subtype C prophylactic vaccine (DNA prime: ADVAX and MVA boost: TBC-M4)
Trial: 26498057
Drug: Testosterone solution
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone solution 2% (60 mg topical, once daily)
Trial: 12088970
Drug: IV Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV Fentanyl (12.5 microg administered immediately after spinal anesthesia)
Trial: 1844926
Drug: Ad-libitum feeding
RxNorm normalized name: SET,FEEDING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad-libitum feeding by oral route (Group C)
Trial: 6499512
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg spiramycin 3-times daily for 3 days
Trial: 6499512
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg erythromycin 3-times daily for 5 days
Trial: 26853792
Drug: lidocaine gel+isotonic
RxNorm normalized name: lidocaine Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lidocaine gel+isotonic spray
Trial: 18373315
Drug: CVVHDF (pre-dilution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVVHDF (pre-dilution volume of 600 mls/h with a dialysate dose of 1 L)
Trial: 7724752
Drug: Contrast material
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast material concentration of 240 mg of iodine per milliliter
Trial: 6356317
Drug: Sucralfate (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate (2 tablets of 500 mg 4 times daily)
Trial: 31062349
Drug: AVP-825 (22
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVP-825 (22 mg)
Trial: 11826205
Drug: High-dose dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dexamethasone (0.5 mg/kg/d for 3 days)
Trial: 11826205
Drug: Low-dose dexamethasone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose dexamethasone (0.2 mg/kg/d for 3 days and 0.1 mg/kg/d for 4 days)
Trial: 7029149
Drug: Intrapleural BCG
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrapleural BCG treatment
Trial: 26800177
Drug: Implants with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implants with anodized surfaces (ANO)
Trial: 26800177
Drug: Implants treated
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Implants treated by acid (AC)
Trial: 25304922
Drug: Proactive feeding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proactive feeding regimen (PFR), starting with 100 mL/kg/day and gradually increasing to 200 mL/kg/day by day 4.
Trial: 25304922
Drug: Standard feeding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard feeding regimen, starting with 60 mL/kg/day and gradually increasing to 170 mL/kg/day by day 9.
Trial: 22436957
Drug: Autologous MSC
RxNorm normalized name: AUTOLOGOUS MSC-NTF
DrugBank: Debamestrocel (DB17934)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous MSC plus standard-dose CNI
Trial: 19505968
Drug: 0.8 ml
RxNorm normalized name: ethanol 0.8 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 ml kg(‐1) of contrast material (350 mgI ml(‐1)) injected with a fixed duration of 10 s (Group B)
Trial: 16437721
Drug: 90 mL
RxNorm normalized name: 190 ML Infugem 10 MG/ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mL of sodium phosphate (NaP) in a split regimen of two 45 mL doses separated by 12 h
Trial: 16437721
Drug: 4 L
RxNorm normalized name: PEG-4 laurate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 L of polyethylene glycol (PEG)
Trial: 8604274
Drug: Prednisone 2
RxNorm normalized name: prednisone 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone 2 mg/kg/day for 2 weeks
Trial: 1720796
Drug: Desferal (desferrioxamine)
DrugBank: Deferoxamine (DB00746)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desferal (desferrioxamine) 0.1 mg/ml to 100 mg/ml
Trial: 1720796
Drug: Cetirizine 10
RxNorm normalized name: cetirizine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine 10 mg (H1 antagonist)
Trial: 24491642
Drug: Individualized ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Individualized ranibizumab treatment (prior ranibizumab)
Trial: 24491642
Drug: Individualized ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Individualized ranibizumab treatment (prior ranibizumab + laser)
Trial: 9524980
Drug: +/- pindolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: +/- pindolol (30 mg, oral dose)
Trial: 7640144
Drug: Sodium acid
RxNorm normalized name: sodium acid citrate
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium acid pyrophosphate (SAPP) 1.1 g/200 ml
Trial: 7494824
Drug: Mannitol 2.264
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mannitol 2.264 g/200 ml
Trial: 2707251
Drug: Vigabatrin (VGB)
DrugBank: Vigabatrin (DB01080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vigabatrin (VGB) at doses ranging from 1 to 4 g/day for 13-15 months
Trial: 73849
Drug: Levodopa with
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levodopa with carbidopa 66 mg/day